- Corporate Officers - C
- Cohen Fred E
Insider Trading History of Cohen Fred E
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Cohen Fred E since 2008.
This trader's CIK number is 1339358.
At the time of last reporting, Cohen Fred E was the Director of Intellia Therapeutics, Inc.. (stock ticker symbol NTLA).
Also see all insider trading activities at Intellia Therapeutics, Inc..
Note that in the past
Cohen Fred E also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Genomic Health Inc (GHDX) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2018 | GHDX | 0 | $0 | 26,500 | $1,846,762 | 26,500 | $774,397 |
| 2017 | GHDX | 0 | $0 | 33,000 | $989,883 | 33,000 | $565,866 |
| 2012 | GHDX | 0 | $0 | 0 | $0 | 8,250 | $88,522 |
| 2008 | GHDX | 0 | $0 | 0 | $0 | 5,201 | $2,995 |
Yearly summary of insider trading at Urogen Pharma Ltd. (URGN) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | URGN | 0 | $0 | 0 | $0 | 15,000 | $254,849 |
Yearly summary of insider trading at Intellia Therapeutics, Inc. (NTLA) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | NTLA | 0 | $0 | 0 | $0 | 20,000 | $275,600 |
Yearly summary of insider trading at Biocryst Pharmaceuticals Inc (BCRX) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | BCRX | 0 | $0 | 54,250 | $294,035 | 54,250 | $231,647 |
| 2015 | BCRX | 0 | $0 | 0 | $0 | 100,000 | $129,000 |
Yearly summary of insider trading at Veracyte, Inc. (VCYT) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | VCYT | 0 | $0 | 40,000 | $1,085,920 | 10,000 | $76,000 |
| 2019 | VCYT | 0 | $0 | 0 | $0 | 40,000 | $368,200 |
Yearly summary of insider trading at Five Prime Therapeutics, Inc. (FPRX) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2016 | FPRX | 0 | $0 | 0 | $0 | 24,695 | $209,833 |
Yearly summary of insider trading at Caredx, Inc. (CDNA) by Cohen Fred E
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | CDNA | 0 | $0 | 0 | $0 | 15,000 | $221,100 |
| 2020 | CDNA | 0 | $0 | 0 | $0 | 16,424 | $85,733 |
| 2019 | CDNA | 0 | $0 | 0 | $0 | 15,765 | $109,677 |
| 2018 | CDNA | 0 | $0 | 0 | $0 | 15,000 | $18,300 |
Insider trading activities at 7 companies by Cohen Fred E:
1. Genomic Health Inc (GHDX)
2. Urogen Pharma Ltd. (URGN)
3. Intellia Therapeutics, Inc. (NTLA)
4. Biocryst Pharmaceuticals Inc (BCRX)
5. Veracyte, Inc. (VCYT)
6. Five Prime Therapeutics, Inc. (FPRX)
7. Caredx, Inc. (CDNA)
Table 1. Insider trading of Genomic Health Inc (GHDX) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2018-11-08 | GHDX | Option Ex | 10,000 | 27.75 | 277,500 |
| 2018-11-08 | GHDX | Sale | 10,000 | 87.36 | 873,560 |
| 2018-09-06 | GHDX | Option Ex | 8,250 | 34.44 | 284,130 |
| 2018-09-06 | GHDX | Sale | 8,250 | 61.51 | 507,457 |
| 2018-08-07 | GHDX | Option Ex | 8,250 | 25.79 | 212,767 |
| 2018-08-07 | GHDX | Sale | 8,250 | 56.45 | 465,745 |
| 2017-05-19 | GHDX | Option Ex | 8,250 | 14.37 | 118,552 |
| 2017-05-19 | GHDX | Sale | 8,250 | 29.55 | 243,746 |
| 2017-05-18 | GHDX | Sale | 16,500 | 29.88 | 493,036 |
| 2017-05-18 | GHDX | Option Ex | 16,500 | 18.05 | 297,742 |
| 2017-05-16 | GHDX | Option Ex | 8,250 | 18.13 | 149,572 |
| 2017-05-16 | GHDX | Sale | 8,250 | 30.68 | 253,101 |
| 2012-08-01 | GHDX | Option Ex | 8,250 | 10.73 | 88,522 |
| 2008-02-19 | GHDX | Option Ex | 5,201 | .58 | 2,995 |
Table 2. Insider trading of Urogen Pharma Ltd. (URGN) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-02-06 | URGN | Option Ex | 15,000 | 16.99 | 254,849 |
Table 3. Insider trading of Intellia Therapeutics, Inc. (NTLA) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-01-20 | NTLA | Option Ex | 20,000 | 13.78 | 275,600 |
Table 4. Insider trading of Biocryst Pharmaceuticals Inc (BCRX) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-09-18 | BCRX | Option Ex | 54,250 | 4.27 | 231,647 |
| 2017-09-18 | BCRX | Sale | 54,250 | 5.42 | 294,035 |
| 2015-01-08 | BCRX | Option Ex | 100,000 | 1.29 | 129,000 |
Table 5. Insider trading of Veracyte, Inc. (VCYT) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-10-19 | VCYT | Option Ex | 10,000 | 7.60 | 76,000 |
| 2020-05-18 | VCYT | Sale | 40,000 | 27.15 | 1,085,920 |
| 2019-08-02 | VCYT | Option Ex | 40,000 | 9.21 | 368,200 |
Table 6. Insider trading of Five Prime Therapeutics, Inc. (FPRX) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2016-01-11 | FPRX | Option Ex | 24,695 | 8.50 | 209,833 |
Table 7. Insider trading of Caredx, Inc. (CDNA) by Cohen Fred E
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-01-06 | CDNA | Option Ex | 15,000 | 14.74 | 221,100 |
| 2020-09-21 | CDNA | Option Ex | 16,424 | 5.22 | 85,733 |
| 2019-07-11 | CDNA | Option Ex | 15,765 | 6.96 | 109,677 |
| 2018-08-28 | CDNA | Option Ex | 15,000 | 1.22 | 18,300 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Cohen Fred E
(Director of Intellia Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.